Show simple item record

Authordc.contributor.authorVillena, Rodolfo 
Authordc.contributor.authorGonzález, Claudio A. es_CL
Authordc.contributor.authorNalegach, M. Elisa es_CL
Authordc.contributor.authorVásquez, Alexandra es_CL
Authordc.contributor.authorVillareal, Marcela es_CL
Authordc.contributor.authorDrago Thibaut, Michele es_CL
Admission datedc.date.accessioned2015-01-07T12:49:21Z
Available datedc.date.available2015-01-07T12:49:21Z
Publication datedc.date.issued2014
Cita de ítemdc.identifier.citationRev Chilena Infectol 2014; 31 (3): 249-253en_US
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/129587
General notedc.descriptionArtículo de publicación SciELOen_US
Abstractdc.description.abstractBackground: In critically ill pediatric patients vancomycin distribution and elimination is altered underscoring the need for pharmacokinetic monitoring; however the therapeutic trough ranges have not been validated for children. Objective: To describe the pharmacokinetics of intravenous vancomycin in critically ill pediatric patients using plasmatic vancomycin monitoring. Methods: Retrospective, descriptive study performed in a paediatric critical care unit. Vancomycin serum levels (Cmin and Cpeak), t ½ and Vd were determined in 1 month to 12 year old patients receiving > 40 mg per-kg-per day. Plasmatic levels were measured at therapy onset and during follow up, evaluating the proportion of trough level determinations within therapeutic range, the average trough concentration, and the Cpeak achieved. Results: A total of 65 plasmatic vancomycin monitorings were analysed in 45 patients. The average values for Ctrough, Cpeak, t1/2and Vd were 10.4 μg/mL, 22.7 μg/mL, 3,1 h and 0.7 L/kg, respectively. An average dose of 47,1 mg/kg/day achieved initial Ctrough levels< 10 mg/mL in 60% of patients (n = 27), between 10 and 14,9 μg/mL in 22,2% (n = 10), between 15 to 20 μg/mL in 4% (n: 2), and > 20 μg/mL in 13,3% (n: 6). Conclusions: Vancomycin doses of 40 mg/kg/day are insufficient for critically ill paediatric patients without renal failure. A higher starting dose and monitoring of plasma levels must be considered in this population.
Lenguagedc.language.isoesen_US
Publisherdc.publisherSociedad Chilena de Infectología
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectVancomycinen_US
Títulodc.titleMonitoreo terapéutico de vancomicina intravenosa en una unidad de paciente crítico pediátricoen_US
Title in another languagedc.title.alternativeTherapeutic monitoring of intravenous vancomycin in a pediatric critical care uniten_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile